Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Evaluating treatment and employment outcomes in adults with prescription opioid use disorder initiating methadone maintenance or buprenorphine/naloxone opioid agonist therapies in a pan-Canadian pragmatic randomized clinical trial

FY 2023-24

Summary
Since 2016, Canada has been facing a national opioid overdose crisis that continues to have devastating effects on people who use opioids, their families, and communities across the country, and is shaped by a wide range of factors. Opioid agonist therapies (OATs), such as methadone and buprenorphine/naloxone (BUP-NX), are considered first-line treatment for people with opioid use disorder (OUD) and have shown to reduce withdrawal, cravings, and overdoses in this vulnerable population. One factor, employment, has shown to have many positive associations for people with OUD, however, there is limited research on the differences between different OATs like methadone and BUP-NX. For instance, methadone maintenance therapy typically requires daily attendance at a dispensing pharmacy for witnessed ingestion, whereas BUP-NX has a flexible take-home dosing option. As such, there may be employment barriers for people on the strict daily-dosing treatment model of methadone. My project aims to evaluate the bidirectional effects of employment and OAT on treatment outcomes among individuals with OUD who were a part of a pan-Canadian pragmatic clinical trial. I will be using data from OPTIMA, a 24-week pragmatic, open-label, non-inferiority randomized clinical trial that compared the effectiveness of supervised methadone and flexible take-home dosing BUP-NX treatment models among 272 treatment-seeking adults with OUD, conducted between 2017 and 2020 across four provinces in Canada. The proposed research can further the equitable scale-up of evidence-based policies and practices, hopefully contributing to the improvement of addiction care and harm reduction for people with OUD.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506087
Name
Hajirawala Sahitya K
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating treatment and employment outcomes in adults with prescription opioid use disorder initiating methadone maintenance or buprenorphine/naloxone opioid agonist therapies in a pan-Canadian pragmatic randomized clinical trial
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Buprenorphine/Naloxone; Employment; Methadone; Opioid Agonist Therapy; Opioid Use Disorder; Randomized Controlled Trial; Retention; Social Determinants Of Health; Substance Use; Treatment
Abstract
Since 2016, Canada has been facing a national opioid overdose crisis that continues to have devastating effects on people who use opioids, their families, and communities across the country, and is shaped by a wide range of factors. Opioid agonist therapies (OATs), such as methadone and buprenorphine/naloxone (BUP-NX), are considered first-line treatment for people with opioid use disorder (OUD) and have shown to reduce withdrawal, cravings, and overdoses in this vulnerable population. One factor, employment, has shown to have many positive associations for people with OUD, however, there is limited research on the differences between different OATs like methadone and BUP-NX. For instance, methadone maintenance therapy typically requires daily attendance at a dispensing pharmacy for witnessed ingestion, whereas BUP-NX has a flexible take-home dosing option. As such, there may be employment barriers for people on the strict daily-dosing treatment model of methadone. My project aims to evaluate the bidirectional effects of employment and OAT on treatment outcomes among individuals with OUD who were a part of a pan-Canadian pragmatic clinical trial. I will be using data from OPTIMA, a 24-week pragmatic, open-label, non-inferiority randomized clinical trial that compared the effectiveness of supervised methadone and flexible take-home dosing BUP-NX treatment models among 272 treatment-seeking adults with OUD, conducted between 2017 and 2020 across four provinces in Canada. The proposed research can further the equitable scale-up of evidence-based policies and practices, hopefully contributing to the improvement of addiction care and harm reduction for people with OUD.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hajirawala, Sahitya K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~